Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.53 |
| ▸ | HTR1A | P08908 | 9/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29966 | 0.86 | SLC6A2 (0.61) | SLC6A2HTR1ASLC6A3FPR2PROKR1 | |
| SCHEMBL3125975 | 0.86 | SLC6A2 (0.60) | SLC6A2HTR1ASLC6A3SLC6A4GRIN1 | |
| SCHEMBL17123797 | 0.82 | SLC6A2 (0.57) | SLC6A2HTR1ASLC6A3FPR2PROKR1 | |
| SCHEMBL3115490 | 0.82 | GPR6 (0.41) | GRIN1GRIN2B | |
| SCHEMBL9538522 | 0.81 | SLC6A2 (0.56) | SLC6A2HTR1ASLC6A3FPR2PROKR1 | |
| SCHEMBL2300625 | 0.81 | SLC6A2 (0.50) | SLC6A2HTR1ASLC6A3FPR2PROKR1 | |
| SCHEMBL3118359 | 0.79 | SLC6A2 (0.46) | SLC6A2HTR1ASLC6A3SLC6A4GRIN1 | |
| SCHEMBL234010 | 0.78 | SLC6A2 (0.81) | SLC6A2HTR1ASLC6A3SLC6A4HTR2C | |
| SCHEMBL16571016 | 0.78 | SLC6A2 (0.53) | SLC6A2HTR1ASLC6A3FPR2PROKR1 | |
| SCHEMBL18186077 | 0.78 | SLC6A2 (0.53) | SLC6A2HTR1ASLC6A3FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SLC6A2 475/4885HTR1A 391/4885SLC6A3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.